Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind …

TJ Craig, A Reshef, HH Li, JS Jacobs, JA Bernstein… - The Lancet, 2023 - thelancet.com
Background Hereditary angioedema is a rare and potentially life-threatening genetic
disease that is associated with kallikrein–kinin system dysregulation. Garadacimab …
被引用次数：46 相关文章

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind …

TJ Craig, A Reshef, HH Li, JS Jacobs, JA Bernstein… - The Lancet, 2023 - pure.psu.edu
Background: Hereditary angioedema is a rare and potentially life-threatening genetic
disease that is associated with kallikrein–kinin system dysregulation. Garadacimab …
[PDF] yangmedicine.com

[PDF][PDF] Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind …

TJ Craig, A Reshef, HH Li, JS Jacobs, JA Bernstein… - 2023 - yangmedicine.com
Background Hereditary angioedema is a rare and potentially life-threatening genetic
disease that is associated with kallikrein–kinin system dysregulation. Garadacimab …

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind …

TJ Craig, A Reshef, HH Li, JS Jacobs… - Lancet (London …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Hereditary angioedema is a rare and potentially life-threatening genetic
disease that is associated with kallikrein-kinin system dysregulation. Garadacimab …

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind …

TJ Craig, A Reshef, HH Li, JS Jacobs, JA Bernstein… - 2023 - publica.fraunhofer.de
Background: Hereditary angioedema is a rare and potentially life-threatening genetic
disease that is associated with kallikrein-kinin system dysregulation. Garadacimab …

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind …

TJ Craig, A Reshef, HH Li, JS Jacobs… - The …, 2023 - researchinformation.amsterdamumc …
Background: Hereditary angioedema is a rare and potentially life-threatening genetic
disease that is associated with kallikrein–kinin system dysregulation. Garadacimab …

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind …

TJ Craig, A Reshef, HH Li, JS Jacobs… - Lancet (London …, 2023 - europepmc.org
Background Hereditary angioedema is a rare and potentially life-threatening genetic
disease that is associated with kallikrein-kinin system dysregulation. Garadacimab …

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind …

TJ Craig, A Reshef, HH Li, JS Jacobs, JA Bernstein… - The Lancet, 2023 - Elsevier
Background Hereditary angioedema is a rare and potentially life-threatening genetic
disease that is associated with kallikrein–kinin system dysregulation. Garadacimab …

[引用][C] Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind …

TJ Craig, A Reshef, HH Li, JS Jacobs, JA Bernstein… - The Lancet, 2023 - cir.nii.ac.jp
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema
prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled …